Logo image of ACLS

AXCELIS TECHNOLOGIES INC (ACLS) Stock Fundamental Analysis

USA - NASDAQ:ACLS - US0545402085 - Common Stock

79.19 USD
-5.42 (-6.41%)
Last: 10/10/2025, 9:08:52 PM
78.78 USD
-0.41 (-0.52%)
After Hours: 10/10/2025, 9:08:52 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to ACLS. ACLS was compared to 112 industry peers in the Semiconductors & Semiconductor Equipment industry. ACLS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ACLS is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

ACLS had positive earnings in the past year.
In the past year ACLS had a positive cash flow from operations.
ACLS had positive earnings in each of the past 5 years.
In the past 5 years ACLS always reported a positive cash flow from operatings.
ACLS Yearly Net Income VS EBIT VS OCF VS FCFACLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

1.2 Ratios

With an excellent Return On Assets value of 11.97%, ACLS belongs to the best of the industry, outperforming 83.04% of the companies in the same industry.
With an excellent Return On Equity value of 15.50%, ACLS belongs to the best of the industry, outperforming 80.36% of the companies in the same industry.
ACLS has a better Return On Invested Capital (12.23%) than 83.93% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ACLS is significantly above the industry average of 10.95%.
The 3 year average ROIC (21.34%) for ACLS is well above the current ROIC(12.23%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 11.97%
ROE 15.5%
ROIC 12.23%
ROA(3y)17.39%
ROA(5y)14.66%
ROE(3y)25.25%
ROE(5y)20.89%
ROIC(3y)21.34%
ROIC(5y)18.4%
ACLS Yearly ROA, ROE, ROICACLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

With a decent Profit Margin value of 17.69%, ACLS is doing good in the industry, outperforming 79.46% of the companies in the same industry.
In the last couple of years the Profit Margin of ACLS has grown nicely.
With a decent Operating Margin value of 17.81%, ACLS is doing good in the industry, outperforming 75.89% of the companies in the same industry.
In the last couple of years the Operating Margin of ACLS has grown nicely.
ACLS has a Gross Margin (44.90%) which is in line with its industry peers.
In the last couple of years the Gross Margin of ACLS has remained more or less at the same level.
Industry RankSector Rank
OM 17.81%
PM (TTM) 17.69%
GM 44.9%
OM growth 3Y2.52%
OM growth 5Y24.03%
PM growth 3Y9.84%
PM growth 5Y31.85%
GM growth 3Y1.09%
GM growth 5Y1.22%
ACLS Yearly Profit, Operating, Gross MarginsACLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

9

2. Health

2.1 Basic Checks

ACLS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ACLS has less shares outstanding than it did 1 year ago.
ACLS has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ACLS has an improved debt to assets ratio.
ACLS Yearly Shares OutstandingACLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ACLS Yearly Total Debt VS Total AssetsACLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 7.35 indicates that ACLS is not in any danger for bankruptcy at the moment.
ACLS's Altman-Z score of 7.35 is fine compared to the rest of the industry. ACLS outperforms 66.96% of its industry peers.
The Debt to FCF ratio of ACLS is 0.35, which is an excellent value as it means it would take ACLS, only 0.35 years of fcf income to pay off all of its debts.
ACLS has a better Debt to FCF ratio (0.35) than 81.25% of its industry peers.
ACLS has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ACLS's Debt to Equity ratio of 0.04 is fine compared to the rest of the industry. ACLS outperforms 61.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.35
Altman-Z 7.35
ROIC/WACC1.05
WACC11.66%
ACLS Yearly LT Debt VS Equity VS FCFACLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

ACLS has a Current Ratio of 6.01. This indicates that ACLS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 6.01, ACLS belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
A Quick Ratio of 4.26 indicates that ACLS has no problem at all paying its short term obligations.
The Quick ratio of ACLS (4.26) is better than 74.11% of its industry peers.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 4.26
ACLS Yearly Current Assets VS Current LiabilitesACLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

ACLS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.37%.
The Earnings Per Share has been growing by 64.54% on average over the past years. This is a very strong growth
Looking at the last year, ACLS shows a very negative growth in Revenue. The Revenue has decreased by -19.38% in the last year.
ACLS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.30% yearly.
EPS 1Y (TTM)-28.37%
EPS 3Y28.48%
EPS 5Y64.54%
EPS Q2Q%-27.1%
Revenue 1Y (TTM)-19.38%
Revenue growth 3Y15.4%
Revenue growth 5Y24.3%
Sales Q2Q%-24.16%

3.2 Future

The Earnings Per Share is expected to decrease by -6.87% on average over the next years.
The Revenue is expected to decrease by -4.79% on average over the next years.
EPS Next Y-31.47%
EPS Next 2Y-16.47%
EPS Next 3Y-6.87%
EPS Next 5YN/A
Revenue Next Year-22.15%
Revenue Next 2Y-9.31%
Revenue Next 3Y-4.79%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ACLS Yearly Revenue VS EstimatesACLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
ACLS Yearly EPS VS EstimatesACLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 15.23, which indicates a correct valuation of ACLS.
Based on the Price/Earnings ratio, ACLS is valued cheaper than 91.96% of the companies in the same industry.
When comparing the Price/Earnings ratio of ACLS to the average of the S&P500 Index (27.02), we can say ACLS is valued slightly cheaper.
With a Price/Forward Earnings ratio of 18.46, ACLS is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ACLS is valued a bit cheaper than the industry average as 77.68% of the companies are valued more expensively.
ACLS's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.57.
Industry RankSector Rank
PE 15.23
Fwd PE 18.46
ACLS Price Earnings VS Forward Price EarningsACLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ACLS indicates a rather cheap valuation: ACLS is cheaper than 92.86% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ACLS is valued cheaply inside the industry as 86.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 20.26
EV/EBITDA 9.09
ACLS Per share dataACLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The excellent profitability rating of ACLS may justify a higher PE ratio.
A cheap valuation may be justified as ACLS's earnings are expected to decrease with -6.87% in the coming years.
PEG (NY)N/A
PEG (5Y)0.24
EPS Next 2Y-16.47%
EPS Next 3Y-6.87%

More info and screens

0

5. Dividend

5.1 Amount

ACLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXCELIS TECHNOLOGIES INC

NASDAQ:ACLS (10/10/2025, 9:08:52 PM)

After market: 78.78 -0.41 (-0.52%)

79.19

-5.42 (-6.41%)

Chartmill FA Rating
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-29 2025-10-29/amc
Inst Owners105.9%
Inst Owner Change0.01%
Ins Owners0.96%
Ins Owner Change9.51%
Market Cap2.49B
Analysts72.86
Price Target99.26 (25.34%)
Short Float %15.11%
Short Ratio8.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)107.85%
Min EPS beat(2)51.76%
Max EPS beat(2)163.95%
EPS beat(4)4
Avg EPS beat(4)59.67%
Min EPS beat(4)2.16%
Max EPS beat(4)163.95%
EPS beat(8)8
Avg EPS beat(8)36.38%
EPS beat(12)12
Avg EPS beat(12)29.49%
EPS beat(16)16
Avg EPS beat(16)28.03%
Revenue beat(2)2
Avg Revenue beat(2)2.57%
Min Revenue beat(2)2.12%
Max Revenue beat(2)3.02%
Revenue beat(4)3
Avg Revenue beat(4)1.2%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)3.02%
Revenue beat(8)7
Avg Revenue beat(8)1.46%
Revenue beat(12)11
Avg Revenue beat(12)2.07%
Revenue beat(16)15
Avg Revenue beat(16)2.39%
PT rev (1m)0%
PT rev (3m)11.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.67%
EPS NY rev (1m)0.06%
EPS NY rev (3m)25.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.4%
Valuation
Industry RankSector Rank
PE 15.23
Fwd PE 18.46
P/S 2.78
P/FCF 20.26
P/OCF 17.99
P/B 2.43
P/tB 2.43
EV/EBITDA 9.09
EPS(TTM)5.2
EY6.57%
EPS(NY)4.29
Fwd EY5.42%
FCF(TTM)3.91
FCFY4.94%
OCF(TTM)4.4
OCFY5.56%
SpS28.52
BVpS32.54
TBVpS32.54
PEG (NY)N/A
PEG (5Y)0.24
Profitability
Industry RankSector Rank
ROA 11.97%
ROE 15.5%
ROCE 13.92%
ROIC 12.23%
ROICexc 23.5%
ROICexgc 23.5%
OM 17.81%
PM (TTM) 17.69%
GM 44.9%
FCFM 13.71%
ROA(3y)17.39%
ROA(5y)14.66%
ROE(3y)25.25%
ROE(5y)20.89%
ROIC(3y)21.34%
ROIC(5y)18.4%
ROICexc(3y)45.35%
ROICexc(5y)37.49%
ROICexgc(3y)45.35%
ROICexgc(5y)37.49%
ROCE(3y)24.29%
ROCE(5y)20.95%
ROICexcg growth 3Y-3.61%
ROICexcg growth 5Y39%
ROICexc growth 3Y-3.61%
ROICexc growth 5Y39%
OM growth 3Y2.52%
OM growth 5Y24.03%
PM growth 3Y9.84%
PM growth 5Y31.85%
GM growth 3Y1.09%
GM growth 5Y1.22%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.35
Debt/EBITDA 0.24
Cap/Depr 91.25%
Cap/Sales 1.73%
Interest Coverage 250
Cash Conversion 78.35%
Profit Quality 77.5%
Current Ratio 6.01
Quick Ratio 4.26
Altman-Z 7.35
F-Score6
WACC11.66%
ROIC/WACC1.05
Cap/Depr(3y)109.12%
Cap/Depr(5y)96.53%
Cap/Sales(3y)1.4%
Cap/Sales(5y)1.41%
Profit Quality(3y)77.07%
Profit Quality(5y)99.84%
High Growth Momentum
Growth
EPS 1Y (TTM)-28.37%
EPS 3Y28.48%
EPS 5Y64.54%
EPS Q2Q%-27.1%
EPS Next Y-31.47%
EPS Next 2Y-16.47%
EPS Next 3Y-6.87%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.38%
Revenue growth 3Y15.4%
Revenue growth 5Y24.3%
Sales Q2Q%-24.16%
Revenue Next Year-22.15%
Revenue Next 2Y-9.31%
Revenue Next 3Y-4.79%
Revenue Next 5YN/A
EBIT growth 1Y-38.8%
EBIT growth 3Y18.31%
EBIT growth 5Y54.17%
EBIT Next Year-33.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-49.07%
FCF growth 3Y-3.13%
FCF growth 5YN/A
OCF growth 1Y-45.47%
OCF growth 3Y-2.13%
OCF growth 5YN/A